Author: Jeff Forslund

Advanced Endometrial Cancer: Making Informed Treatment Decisions and Accessing Clinical Trials

Post author By Jeff Forslund
Post date August 15, 2025

Advanced Endometrial Cancer

Making Informed Treatment Decisions and Accessing Clinical Trials

Endometrial cancer is the most common gynecologic cancer—and for many people, it comes with more questions than answers. In this honest, expert-led conversation, Dr. Brian Slomovitz from Mount Sinai Medical Center in Florida and The Patient Story’s Stephanie Chuang break down the latest in diagnosis, treatment options, and how to have better conversations with your care team.

Learn about early warning signs, key risk factors like obesity and PCOS, and how biomarker testing and clinical trials are changing the standard of care—especially for advanced and recurrent disease.

Topics:

Warning signs and symptoms to watch for, including post-menopausal bleeding
Risk factors that raise your chances, like obesity, PCOS, and Lynch syndrome
How specialists use biomarker testing to personalize care
Treatment options beyond chemotherapy, including immunotherapy and hormone therapy
What clinical trials are, who they’re for, and how to access them—even remotely
Why it’s okay (and important) to get a second or third opinion

Thank you to Karyopharm for its support of our patient education program. The Patient Story retains full editorial control over all content.

Register for this informative program then invite a Friend or Care Partner.

Advanced Endometrial Cancer: Making Informed Treatment Decisions and Accessing Clinical Trials

Hosted by The Patient Story Team

Advanced endometrial cancer is not one-size-fits-all. In this free educational program, expert Dr. Brian Slomovitz joins The Patient Story to explain how biomarker testing, new therapies, and clinical trials are giving patients more options than ever before.

Blood Tests Medical Tests Myelofibrosis Myeloproliferative neoplasms (MPNs) Patient Events

MPN Lab Results: Feel More Confident Reading Your Labs

Post author By Jeff Forslund
Post date August 6, 2025

MPN Lab Results: Feel More Confident Reading Your Labs

Join an expert-led webinar - Pick a date and time that works best for you.

If you’re living with an MPN—like polycythemia vera, essential thrombocythemia, or myelofibrosis—your blood work plays a key role in both diagnosis and ongoing care. This program explains how lab results help guide treatment decisions, track disease changes, and manage symptoms or side effects over time.

Join Dr. Aaron Gerds of Cleveland Clinic and longtime MPN patient advocate Ruth Fein Revell as they explore how mutation testing—including JAK2, CALR, and MPL—can shape care, what trends to watch in your lab results, and how to have more confident conversations with your doctor.

Topics:

What CBC, CMP, and mutation testing reveal in MPNs
How doctors use blood work to monitor disease and guide treatment
Understanding JAK2, CALR, and MPL mutations
What allele burden means—and how it changes over time
When a bone marrow biopsy is needed (and when it might not be)
How to talk with your doctor about labs, results, and treatment options

Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed with ET, PV, or myelofibrosis or have been living with a myeloproliferative neoplasm for years, this conversation is for you.

MPN Lab Results: Feel More Confident Reading Your Labs

Hosted by The Patient Story Team

Blood work is essential in diagnosing and managing MPNs—but most patients are never taught what the numbers mean. In this program, Dr. Aaron Gerds of Cleveland Clinic breaks down key lab tests, explaining how doctors use them to make decisions about diagnosis, treatment, and monitoring.

Tags lab results

Medical Tests Patient Events Waldenström’s Macroglobulinemia

Waldenström’s: What IgM and Other Lab Markers Tell Us

Post author By Jeff Forslund
Post date August 6, 2025

Waldenström’s Lab Tests Revealed: What IgM and Other Lab Markers Tell Us

Join an expert-led webinar - Pick a date and time that works best for you.

Join one of the world’s leading WM experts, Dr. Stephen Ansell of Mayo Clinic, in a conversation with patient advocate Annmarie Seldon. Together, they offer practical insights on how to interpret your results and what questions to ask at your next appointment. Whether you’re newly diagnosed, in active treatment, or navigating remission, this program will help you better understand your disease and feel more confident managing it.

Topics:

What IgM, hemoglobin, and other markers reveal in WM
Role of MYD88 and CXCR4 in confirming diagnosis and guiding care
How doctors decide when it’s time to begin treatment
Tracking treatment response through changes in bloodwork
What MRD means and where it fits in the future of WM care
Why ongoing lab monitoring is key—even in remission

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed or have been living with waldenström macroglobulinemia (WM) for years, this conversation is for you.

Waldenström’s: What IgM and Other Lab Markers Tell Us

Hosted by The Patient Story Team

In this expert-led session, Dr. Stephen Ansell of Mayo Clinic breaks down how lab results like IgM, genetic mutations, and CBC results inform diagnosis, treatment timing, and monitoring in Waldenström’s.

Tags lab results

CLL Patient Events

CLL Lab Tests Revealed: Navigating Care with Confidence

Post author By Jeff Forslund
Post date July 29, 2025

CLL Lab Tests Revealed: Navigating Care with Confidence

Join an expert-led webinar - Pick the date and time that works best for you.

For many living with CLL, lab tests are a constant part of the experience—but understanding what they mean isn’t always easy. In this in-depth conversation, CLL expert Dr. Adam Kittai joins longtime patient advocate Michele Nadeem-Baker to explore how blood tests guide real-world care decisions.

From identifying when “watch and wait” should shift to active treatment, to interpreting genetic markers like IGHV and TP53, to understanding MRD testing and remission—this discussion helps demystify what’s behind the numbers and how they shape your care.

Topics:

How ongoing blood tests guide CLL monitoring and treatment timing
What genetic tests like IGHV, TP53, and FISH reveal about your prognosis
How MRD (minimal residual disease) testing is used to assess remission
Differences in follow-up for time-limited vs. continuous treatment
Questions to ask about your labs—and what they mean for your future care

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed or have been living with CLL for years, this conversation is for you.

CLL Labs Revealed: Navigating Care with Confidence

Hosted by The Patient Story Team

What do your CLL blood test results actually mean? In this educational program, Dr. Adam Kittai and CLL patient advocate Michele Nadeem-Baker explain how common tests—like CBC, IGHV, and MRD—help guide diagnosis, treatment, and prognosis.

Tags lab results

Follicular Lymphoma Non-Hodgkin Lymphoma Patient Events

Follicular Lymphoma Lab Tests Explained with Dr. Celeste Bello

Post author By Jeff Forslund
Post date July 29, 2025

Follicular Lymphoma Lab Tests Explained: How Blood, Biopsy, and Imaging Tests Impact Treatment Decisions

Join an expert-led webinar - Pick the date and time that works best for you.

How do blood test results help guide care for follicular lymphoma (FL)? What do terms like CBC, LDH, beta-2 microglobulin, and FLIPI really mean—and how are they used in monitoring and treatment planning?

In this in-depth discussion, Stephanie Chuang speaks with FL expert Dr. Celeste Bello of Moffitt Cancer Center. Together, they walk through the most important blood work and imaging tools in FL, when and how they’re used. They cover what biopsy types matter most, and how criteria like FLIPI, POD24, and GELF help determine when to start treatment.

Topics:

What blood tests and scans reveal in FL—and when they matter most
Biopsies and diagnostic tools: flow cytometry, IHC, and imaging
Understanding prognostic tools like FLIPI, POD24, and GELF criteria
Monitoring during observation and treatment: labs, scans, and red flags
Why speaking up about subtle changes can shape your care plan

Register for this informative program then invite a Friend or Care Partner.

This program is designed to empower patients and care partners with clarity around tests—and when to speak up.

Follicular Lymphoma: Your Lab Tests Explained

Hosted by The Patient Story Team

Explore how blood tests, biopsies, and scans guide follicular lymphoma care—from diagnosis and observation to active treatment. Dr. Celeste Bello breaks down what lab markers really mean and when to act on them.

Tags lab results

DLBCL Patient Events

DLBCL Tests Explained: How Blood, Biopsy, and Imaging Tests Impact Treatment Decisions

Post author By Jeff Forslund
Post date July 14, 2025

DLBCL Tests Explained: How Blood, Biopsy, and Imaging Tests Impact Treatment Decisions

Join an expert-led webinar - Pick the date and time that works best for you.

Diffuse large B-cell lymphoma (DLBCL) is fast-moving, but often curable—especially when caught early. Blood work plays a key role throughout diagnosis, treatment, and remission, though many patients are left unsure of what their lab results really mean.

In this discussion, Dr. Robyn Stacy-Humphries, a three-time DLBCL survivor, moderates a conversation with lymphoma expert Dr. Tycel Phillips of City of Hope. Together, they unpack what blood tests can (and can’t) tell you, how biopsies and imaging are used, and what markers like LDH, neutrophils, and immunoglobulins mean during and after chemotherapy, CAR T-cell therapy, and beyond.

Topics:

Learn what your CBC, LDH, and metabolic panels really mean during treatment
Understand the role of imaging, biopsies, and why blood tests alone don’t diagnose DLBCL
Get clarity on neutrophils, immunoglobulin levels, and why some “abnormal” results are not dangerous
Find out how often blood work is done during and after treatment like R-CHOP, CAR T-cell therapy, or bispecifics
Hear what’s ahead in MRD and liquid biopsy research for DLBCL monitoring

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed or have been living with diffuse large B-cell lymphoma for years, this conversation is for you.

DLBCL Tests Explained: How Blood, Biopsy, and Imaging Tests Impact Treatment Decisions

Hosted by The Patient Story Team

DLBCL is fast-moving, but often curable—especially when caught early. In this discussion, Dr. Robyn Stacy-Humphries, a three-time DLBCL survivor, moderates a conversation with lymphoma expert Dr. Tycel Phillips of City of Hope.

Tags lab results

Acute Myeloid Leukemia Patient Events

AML Labs Explained: What Blood and Bone Marrow Tests Reveal After Diagnosis

Post author By Jeff Forslund
Post date July 14, 2025

AML Labs Explained: What Blood and Bone Marrow Tests Reveal After Diagnosis

Join an expert-led webinar - Pick the date and time that works best for you.

After an AML diagnosis, treatment often begins right away—leaving little time to process what’s happening, let alone what your lab results mean.

In this discussion, AML survivor Steve Buechler speaks with Dr. Alice Mims from The Ohio State University Comprehensive Cancer Center about the key blood and bone marrow tests that guide treatment, track progress, and inform long-term decisions. From CBCs and blast counts to FLT3 and NPM1 mutations, they break down what you need to know moving forward.

Topics:

Learn what your CBC results mean—including white blood cells, hemoglobin, and platelet counts
Understand what blast cells are and why they matter in AML
Hear how bone marrow biopsies and genetic testing (like FLT3 or NPM1) shape your treatment
Get guidance on monitoring your bloodwork during treatment and remission
Know when to consider clinical trials and how MRD tracking may guide next steps

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been through induction treatments or have been living with acute myeloid leukemia for years, this conversation is for you.

AML Labs Explained: What Blood and Bone Marrow Tests Reveal After Diagnosis

Hosted by The Patient Story Team

Dr. Alice Mims from The OSU Comprehensive Cancer Center explains the key blood and bone marrow tests that guide treatment, track progress, and inform long-term decisions.

Tags aml event, lab results

Multiple Myeloma Patient Events

Myeloma Labs: How Blood, Urine, and Imaging Tests Impact Treatment Decisions

Post author By Jeff Forslund
Post date July 14, 2025

Monitoring Myeloma: How Blood, Urine, and Imaging Tests Impact Treatment Decisions

Multiple program dates to pick from! Join over the next 2 weeks or get the replay.

Lab tests play a central role in diagnosing and managing multiple myeloma, yet they can feel confusing and overwhelming.

In this expert conversation, Dr. Brandon Blue of Moffitt Cancer Center sits down with Bryon Daily, a multiple myeloma patient and community leader from The Leukemia & Lymphoma Society, to break it all down in real terms.

They share honest insights on:

Imaging tests explained: X-ray, MRI, PET
Find out how lab work helps guide treatment decisions
What labs indicate a relapse or treatment change
Using biomarkers in clinical trials

From groundbreaking studies to insightful patient stories, MPN Research Foundation is at the forefront of making real change for those directly affected by essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Register for this informative program then invite a Friend or Care Partner.

Whether you’re newly diagnosed or have been living with multiple myeloma for years, this conversation is for you.

Monitoring Myeloma: How Blood, Urine, and Imaging Tests Impact Treatment Decisions

Hosted by The Patient Story Team

Lab tests play a central role in diagnosing and managing multiple myeloma. Dr. Brandon Blue of Moffitt Cancer Center sits down with Bryon Daily, myeloma patient and community leader from The LLS, to break it all down in real terms.

Tags lab results, myeloma event

Myeloproliferative neoplasms (MPNs) Patient Events

MPN Symptom Tracking

Post author By Jeff Forslund
Post date July 8, 2025

Take Charge of Your MPN: Tracking Symptoms & Advocating for Better Care

Join us on Wednesday, July 30, 2025 at 3pm PDT | 6pm EDT (U.S.)

Living with an MPN (myeloproliferative neoplasm) brings challenges that aren’t always visible—but tracking your symptoms can make a powerful difference.

In this free patient-led discussion, MPN advocates Ruth Fein Revell, Nick Napolitano, and Demetria open up about what it means to live proactively with an MPN—whether it’s ET, PV, or MF.

They share honest insights on:

How fatigue, brain fog, itching, and other symptoms show up in real life
Why tracking those symptoms can shape better care and decisions
The emotional weight of living with a chronic cancer—and how to cope
How care partners can support advocacy and communication
The role of clinical trials in expanding future treatment options

Register for this informative program then invite a Friend or Care Partner.

Whether you’re newly diagnosed or have been living with an MPN for years, this conversation is for you.

Take Charge of Your MPN: Tracking Symptoms & Advocating for Better Care

Hosted by The Patient Story Team

In this free patient-led discussion, MPN advocates Ruth, Nick, and Demetria open up about what it means to live proactively with ET, PV, or MF.

Thank you to Incyte and Karyopharm Therapeutics for supporting our patient education program. The Patient Story retains full editorial control over all content.

Tags MPN patient events

Bladder Cancer Patient Events

Bladder Cancer Treatment Options in 2025

Post author By Jeff Forslund
Post date June 20, 2025

Bladder Cancer Breakthroughs 2025

New Treatments & Bladder-Sparing Advances

On Demand Replay Now Available.

Dr. Ashish Kamat from MD Anderson shares the latest on bladder-sparing treatments in 2025—and what questions to ask your doctor.

Select an “On Demand” session to watch right now.
Select a “Replay” session to have a link sent to you.

Bladder cancer care is evolving rapidly, with new treatments offering the potential for longer survival and better quality of life—including the possibility of preserving the bladder.

In this expert-led discussion, MD Anderson’s Dr. Ashish Kamat breaks down the latest in research, emerging therapies, and what patients and care partners need to know now to make informed treatment decisions.

Key Topics Covered:

The different types and stages of bladder cancer, and how they affect treatment decisions
Current standards of care for non-muscle invasive, muscle-invasive, and advanced disease
What’s new in 2025: gene therapy, immunotherapy, and targeted agents
Bladder-sparing strategies and how to talk with your doctor about them
What to know about clinical trials and how to find one that fits your needs
Long-term recovery, side effect support, and life after treatment

We would like to thank our promotional parter, The World Bladder Cancer Patient Coalition (WBCPC), which brings together bladder cancer patient organisations from around the globe to improve the lives of people affected by bladder cancer. They are committed to raising awareness, providing trusted patient information, and ensuring the patient voice is heard in research, policy, and care.

Register for this informative program then invite a Friend or Care Partner – This information is valuable for anyone facing bladder cancer.

Bladder Cancer Breakthroughs 2025: New Treatments & Bladder-Sparing Advances

Hosted by The Patient Story Team

In this expert-led discussion, MD Anderson’s Dr. Ashish Kamat breaks down the latest in research, emerging therapies, and what patients and care partners need to know now to make informed treatment decisions.

Watch On DEMAND!

Thank you to Johnson & Johnson for its support of our patient education program. The Patient Story retains full editorial control over all content.

Tags bladder cancer event, Bladder Cancer Resources